DOW — Dow Inc.

Market sentiment is mixed-to-cautiously optimistic: Q2 2026 earnings beat and management raised cost-savings targets, but the stock remains range-bound near the lower half of its 52-week range, analyst consensus is Hold, and a 4.1% single-day drop on August 25 shows lingering cyclical-demand fear.

The three-year trend is a classic chemical trough and nascent inflection. Revenue ground down from ~$10.9B per quarter in 2024 to $9.46B in Q4 2025, then inflected sharply: Q1 2026 revenue was $9.79B and Q2 2026 jumped to $12.09B (+19.7% YoY). Operating income went from ~$700M in early 2024 to losses through 2025, hit by a $1.04B operating loss in Q4 2025, then rebounded to $882M in Q2 2026. Net income swung from -$835M in Q2 2025 to +$721M in Q2 2026, and gross margin expanded from 5.4% to 17.9% YoY. TTM figures are still negative due to the deep 2025 losses, so this is one strong quarter, not yet a proven multi-quarter trend.

As of 2026-08-27, the trailing P/E is meaningless at -16.8x because TTM EPS is -$1.70. The cleaner read: forward P/E is ~12.2x on the next-fiscal-year EPS estimate of $2.48, P/S is 0.53x versus the 5-year average of 0.67x, P/B is 0.88x against book value of roughly $33.80 per share, and the dividend yield is 4.15%. That is cheap versus DOW's own history, but the low TTM operating margin (-0.1%) and ROIC (0.5%) explain why the market is not paying a mid-cycle multiple yet.

As of 2026-08-27, the market is pricing a muted, sub-normal earnings cycle: $30.33 is only ~12.2x forward EPS, not a big premium for the recovery Q2 hinted at. If next-year EPS actually lands near $2.48, a mid-cycle multiple supports the mid-$30s. If demand stalls and EPS falls back to ~$1.50, the stock would be trading over 20x forward earnings and the support would shift to book value and the dividend. In short, this is a show-me cyclical recovery, not a momentum stock.

As of 2026-08-27, RSI was 47.19, neutral rather than oversold or overbought. Price was 1.44% below the 20-day SMA, 0.99% above the 50-day SMA, and 2.9% below the 200-day SMA. That is a range-bound, trendless technical picture. Entry timing implication: no urgency; the stock is not breaking out, and a patient buyer would prefer either a confirmed break above the 200-day or a retest of the lower $20s.

• Global industrial production and PMI weakness: DOW's volumes track packaging, housing, autos, and general manufacturing, and sluggish global growth is the main demand headwind.
• Interest rates: high borrowing costs continue to pressure construction and durable-goods end markets; central-bank easing would be a meaningful tailwind.
• Chemical supply/demand balance: new global capacity, especially in polyethylene, has kept commodity chemical spreads depressed.
• Energy and feedstock costs: movements in ethane, naphtha, and natural gas directly affect Dow's cost position and margin spreads.
• Trade policy and FX: tariffs and a strong dollar can pressure export competitiveness and international earnings.

• Q3 2026 earnings (expected late October 2026): confirmation that the upgraded >$1.3B self-help savings and the H2 EBITDA uplift from the Barry shutdown and Terneuzen restart are showing up in results.
• Further cost and asset-optimization actions under the 'Transform to Outperform' program.
• A turn in global macro data, interest-rate cuts, or China stimulus that re-rates cyclical demand expectations.
• Continued free-cash-flow generation protecting the $0.35 quarterly dividend and supporting a higher multiple.

• Prolonged chemical oversupply and weak global demand keep margins below mid-cycle, making the current EPS recovery short-lived.
• Execution risk on the $1.3B self-help program, Terneuzen restart, or Barry shutdown benefits.
• Dividend risk if free cash flow deteriorates again; the 4.15% yield is attractive but TTM GAAP profitability is still negative.
• The reported +60% sequential jump in stockholders' equity in Q2 2026 raises book-value and balance-sheet comparability questions that the market has not yet fully explained.

DOW is a reasonable contrarian/cyclical value at $30.33: it trades below book, yields 4.15%, and Q2 2026 showed a sharp profit and cash-flow inflection while management's self-help program is running ahead of plan. The caveat is that the macro demand recovery is unproven and the balance sheet has an unusual recent equity jump, so this is a patient, cycle-aware investment rather than a high-conviction compounder.

Fair value is approximately 14.0x next-fiscal-year EPS of $2.477, which gives $34.68 and rounds to $35.00; that multiple is a mid-cycle multiple for a low-beta, 4.1%-yielding commodity chemical company, slightly below the consensus target's implied 14.6x but above the current 12.2x forward P/E, and it aligns with roughly 1.0x book value on ~$33.80 per share.